This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dr. Charles Abrams Awarded Grant By Muscular Dystrophy Association To Study Charcot-Marie-Tooth Disease

SUNY Downstate Researcher Looks to Gene Mutations for Answers

BROOKLYN, N.Y., May 2, 2012 /PRNewswire-USNewswire/ -- Charles Abrams, M.D., Ph.D., associate professor of neurology and director of the Neuromuscular Division at SUNY Downstate Medical Center, has been awarded a three-year grant totaling $414,787 by the Muscular Dystrophy Association, the premier health organization dedicated to preventing and treating muscle-wasting diseases.

The grant will fund Dr. Abrams' research on the role of connexin protein mutations in Charcot-Marie-Tooth disease. Dr. Abrams is a leading authority on this genetic disorder, for which there is currently no known cure or effective treatment.

Charcot-Marie-Tooth Disease (CMT) is among the neuromuscular disorders seen at the Center for Neuromuscular Disease that Dr. Abrams heads at SUNY Downstate. One of the most common inherited neurological disorders, the disease is named for the three physicians who first described it. Also known as peroneal muscular atrophy, it comprises a group of disorders that damage the peripheral nerves. Symptoms include numbness and pain in the hands and feet, and increasing muscle weakness.

Of the several forms of the disease, Dr. Abrams is concerned with type 1 X-linked CMT or CMT1X. This form affects the central nervous system (CNS) in addition to the peripheral nerves. Patients are susceptible to episodic attacks of CNS dysfunction characterized most commonly by motor weakness and difficulty speaking and less often by disorientation, difficulty breathing, and difficulty swallowing.

In his laboratory at Downstate, Dr. Abrams has been studying the role of connexins (gap junction proteins) in both the peripheral and central nervous system. His ongoing research focuses, in part, on the mechanisms by which CMT1X mutations lead to peripheral neuropathy.

More than 300 mutations in the gene for the connexin 32 protein have been linked to CMT1X. Dr. Abrams and his colleagues will study whether abnormal interactions between mutated connexin 32 protein and a related CNS protein, connexin 47, are the cause of the CNS dysfunction found in the disease.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs